Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

Phase 2 Completed 24 enrolled E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the population pharmacokinetic characteristics of QY201 Tablets in adolescent participants with moderate to severe atopic dermatitis (AD).

Timeline

Start: 2025-06-04
Primary completion: 2025-12-19
Completion: 2025-12-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QY201	Unknown	10 mg	—
Subject	QY201	Unknown	20 mg	—

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

Summary

Timeline

Drugs

Indications